{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T01:38:37Z","timestamp":1778031517995,"version":"3.51.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI068634"],"award-info":[{"award-number":["AI068634"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI068636"],"award-info":[{"award-number":["AI068636"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI106701"],"award-info":[{"award-number":["AI106701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 AI134307"],"award-info":[{"award-number":["K23 AI134307"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>One month of daily rifapentine + isoniazid (1HP) is an effective, ultrashort option for tuberculosis prevention in people with human immunodeficiency virus (HIV). However, rifapentine may decrease antiretroviral drug concentrations and increase the risk of virologic failure. AIDS Clinical Trials Group A5372 evaluated the effect of 1HP on the pharmacokinetics of twice-daily dolutegravir.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A5372 was a multicenter, pharmacokinetic study in people with HIV (\u226518\u2005years) already on dolutegravir-containing antiretroviral therapy with HIV RNA &amp;lt;50 copies\/mL. Participants received daily rifapentine\/isoniazid (600\u2005mg\/300\u2005mg) for 28 days as part of 1HP. Dolutegravir was increased to 50\u2005mg twice daily during 1HP, and intensive pharmacokinetic sampling was performed on day 0 (before 1HP) and on the final day of 1HP treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty-two participants (41% female; 66% Black\/African; median [Q1, Q3] age, 42 [34, 49] years) were included in the pharmacokinetic analysis; 31 had HIV RNA &amp;lt;50 copies\/mL at the end of 1HP dosing. One participant had an HIV RNA of 160 copies\/mL at day 28, with HIV RNA &amp;lt;50 copies\/mL upon repeat testing on day 42. The median (Q1, Q3) dolutegravir trough concentration was 1751\u2005ng\/mL (1195, 2542) on day 0 versus 1987\u2005ng\/mL (1331, 2278) on day 28 (day 28:day 0 geometric mean ratio, 1.05 [90% confidence interval, .93\u20131.2]; P = .43). No serious adverse events were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dolutegravir trough concentrations with 50\u2005mg twice-daily dosing during 1HP treatment were greater than those with standard-dose dolutegravir once daily without 1HP. These pharmacokinetic, virologic, and safety data provide support for twice-daily dolutegravir use in combination with 1HP for tuberculosis prevention.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT04272242.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae183","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T18:34:44Z","timestamp":1712169284000},"source":"Crossref","is-referenced-by-count":3,"title":["Twice-Daily Dolutegravir\u2013Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-0379","authenticated-orcid":false,"given":"Anthony T","family":"Podany","sequence":"first","affiliation":[{"name":"College of Pharmacy, University of Nebraska Medical Center , Omaha"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoninah","family":"Cramer","sequence":"additional","affiliation":[{"name":"Statistical and Data Analysis Center, Harvard School of Public Health , Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjorie","family":"Imperial","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of California , San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L","family":"Rosenkranz","sequence":"additional","affiliation":[{"name":"Statistical and Data Analysis Center, Harvard School of Public Health , Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"Thai Red Cross AIDS Research Center and Center of Excellence in Tuberculosis , Faculty of Medicine, Chulalongkorn University, Bangkok , Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Arduino","sequence":"additional","affiliation":[{"name":"McGovern Medical School, University of Texas Health Science Center at Houston , Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wadzanai","family":"Samaneka","sequence":"additional","affiliation":[{"name":"College of Health Sciences, University of Zimbabwe , Harare"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Gelmanova","sequence":"additional","affiliation":[{"name":"Division of AIDS, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rada","family":"Savic","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of California , San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5826-6037","authenticated-orcid":false,"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Internal Medicine, University of Nebraska Medical Center , Omaha"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[{"name":"Lung Institute, University of Cape Town , South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne F","family":"Luetkemeyer","sequence":"additional","affiliation":[{"name":"College of Medicine, University of California , San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"2024042609560205300_ciae183-B1","volume-title":"Global tuberculosis report 2022","author":"World Health Organization (WHO)","year":"2022"},{"key":"2024042609560205300_ciae183-B2","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"key":"2024042609560205300_ciae183-B3","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1056\/NEJM199902043400507","article-title":"Tuberculosis in patients with human immunodeficiency virus infection","volume":"340","author":"Havlir","year":"1999","journal-title":"N Engl J Med"},{"key":"2024042609560205300_ciae183-B4","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"key":"2024042609560205300_ciae183-B5","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","article-title":"Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial","volume":"384","author":"Rangaka","year":"2014","journal-title":"Lancet"},{"key":"2024042609560205300_ciae183-B6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199709183371201","article-title":"A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus","volume":"337","author":"Whalen","year":"1997","journal-title":"N Engl J Med"},{"key":"2024042609560205300_ciae183-B7","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"2024042609560205300_ciae183-B8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine plus isoniazid for treatment of M. tuberculosis infection in HIV co-infected persons","volume":"30","author":"Sterling","year":"2016","journal-title":"AIDS"},{"key":"2024042609560205300_ciae183-B9","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"2024042609560205300_ciae183-B10","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz pharmacokinetics and pharmacodynamics in HIV-infected persons receiving rifapentine and isoniazid for tuberculosis prevention","volume":"61","author":"Podany","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2024042609560205300_ciae183-B11","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkaa470","article-title":"Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention","volume":"76","author":"Podany","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2024042609560205300_ciae183-B12","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents"},{"key":"2024042609560205300_ciae183-B13","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","author":"World Health Organization (WHO)","year":"2021"},{"key":"2024042609560205300_ciae183-B14","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-020-00898-8","article-title":"Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: an updated review","volume":"59","author":"Podany","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2024042609560205300_ciae183-B15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2019.04.009","article-title":"Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin","volume":"54","author":"Wang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2024042609560205300_ciae183-B16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/QAI.0b013e318276cda9","article-title":"Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects","volume":"62","author":"Dooley","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2024042609560205300_ciae183-B17","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/jac\/dkz068","article-title":"Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide","volume":"74","author":"Cerrone","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2024042609560205300_ciae183-B18","author":"US Food and Drug Administration"},{"key":"2024042609560205300_ciae183-B19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/cid\/ciy082","article-title":"Cytokine-mediated systemic adverse drug reactions in a drug\u2013drug interaction study of dolutegravir with once-weekly isoniazid and rifapentine","volume":"67","author":"Brooks","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024042609560205300_ciae183-B20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40262-016-0424-1","article-title":"Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors","volume":"56","author":"Podany","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"2024042609560205300_ciae183-B21","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: a comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"2024042609560205300_ciae183-B22","author":"Avihingsanon"},{"key":"2024042609560205300_ciae183-B23","author":"Avihingsanon"},{"key":"2024042609560205300_ciae183-B24","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad730","article-title":"Treatment responses to integrase strand-transfer inhibitor-containing antiretroviral regimens in combination with short-course rifapentine-based regimens for latent tuberculosis infection among people with human immunodeficiency virus [manuscript published online ahead of print 5 December 2023]","author":"Lin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2024042609560205300_ciae183-B25","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"key":"2024042609560205300_ciae183-B26","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(23)00081-4","article-title":"Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial","volume":"10","author":"Griesel","year":"2023","journal-title":"Lancet HIV"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae183\/57337616\/ciae183.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae183\/57337616\/ciae183.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T09:56:18Z","timestamp":1714125378000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/advance-article\/doi\/10.1093\/cid\/ciae183\/7639845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":26,"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae183","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,3]]},"article-number":"ciae183"}}